Synergy Pharmaceuticals (NASDAQ:SGYP) : Traders are bullish on Synergy Pharmaceuticals (NASDAQ:SGYP) as it has outperformed the S&P 500 by a wide margin of 2.13% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.11%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.46% in the last 1 week, and is up 3.78% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -54.32% from its 1 Year high price. On Jul 30, 2015, the shares registered one year high at $9.76 and the one year low was seen on Mar 23, 2016. The 50-Day Moving Average price is $3.74 and the 200 Day Moving Average price is recorded at $3.63.
The stock has recorded a 20-day Moving Average of 9.57% and the 50-Day Moving Average is 18.06%.
Synergy Pharmaceuticals (NASDAQ:SGYP): stock turned positive on Friday. Though the stock opened at $4.03, the bulls momentum made the stock top out at $4.14 level for the day. The stock recorded a low of $4.0299 and closed the trading day at $4.12, in the green by 3.26%. The total traded volume for the day was 2,345,086. The stock had closed at $3.99 in the previous days trading.
In an insider trading activity, The officer (Senior Vice President, Finance), of Synergy Pharmaceuticals, Inc., Denoyer Bernard had unloaded 10,000 shares at $7.5 per share in a transaction on September 14, 2015. The total value of transaction was $75,000. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.